

Please type a plus sign (+) inside this box → [+]

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/717,597
		Filing Date	November 21, 2003
		First Named Inventor	Natalie C. TWINE <i>et al.</i>
		Group Art Unit	1631
		Examiner Name	Mary K. Zeman
Total Number of Pages in This Submission	4	Attorney Docket Number	031896-012000 (AM101055)

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Declaration and Power of Attorney <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Application Data Sheet <input checked="" type="checkbox"/> Other Enclosure(s): PTO Form-1449 citing four (4) U.S. patent, one (1) foreign patent, and twenty-six (26) non-patent literature documents and three (3) International Search Reports.
Remarks		<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 19-2380 (031896-012000) for the above identified docket number.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Raymond Van Dyke, Reg. No.34,746 Nixon Peabody LLP 409 9 th Street, N.W. Suite 900 Washington, D.C. 20004-2128
Signature	
Date	September 2, 2005

CERTIFICATE OF MAILING	
CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]	
I hereby certify that this correspondence is being:	
<input type="checkbox"/> deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450	
<input type="checkbox"/> transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at 703-746-4060.	
Date	Signature



Docket No. 031896-012000
(AM101055)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>In re</i> New Patent Application of:)	
Natalie C. TWINE <i>et al</i>)	Group Art Unit: 1631
Serial No.: 10/717,597)	Examiner: Mary K. Zeman
Filed: November 21, 2003)	Confirmation No.: 3640
For: METHODS FOR DIAGNOSING RCC)	
AND OTHER SOLID TUMORS)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

The documents cited in the enclosed Form-PTO-1449 are being submitted within three (3) months of the filing of this application or entry into the national stage of this application, or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

In view of the Official Gazette Notice dated August 5, 2003, copies of the cited U.S. patent documents are not included with this Statement. However, copies of the cited foreign patent and non-patent literature documents are enclosed. Also enclosed are copies of International Search Reports, which were issued during the prosecution of the corresponding and related International applications.


It is requested that the accompanying PTO-1449 be considered and made of record in the above-identified application. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

The Commissioner is hereby authorized to charge any fees connected with this filing, which may be required now, or credit any overpayment to Deposit Account No. 19-2380.

Respectfully submitted,

Date: September 2, 2005

By



Raymond Van Dyke
Registration No. 34,746

NIXON PEABODY LLP
Suite 900
401 9th Street, N.W.
Washington, D.C. 20004-2128
Telephone: (202) 585-8000
Facsimile: (202) 585-8080



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		<i>Complete if Known</i>			
		Application Number	10/717,597		
		Filing Date	November 21, 2003		
		First Named Inventor	Natalie C. TWINE <i>et al.</i>		
		Art Unit	1631		
		Examiner Name	Mary K. Zeman		
Sheet	1	of	2	Attorney Docket Number	031896-012000 (AM101055)

U.S. PATENT DOCUMENTS					
Examiner Initials [*]	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		U.S. - 6,288,220	09-11-2001	KAMBARA, H. <i>et al.</i>	
		U.S. - 6,391,562	05-21-2002	KAMBARA, H. <i>et al.</i>	
		U.S. - 6,303,301	10-16-2001	MACK, D. H. <i>et al.</i>	
		U.S. - 6,087,098	06-11-2000	MCKIERNAN, J. M. <i>et al.</i>	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

FOREIGN PATENT DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 2002/40717 A2	05-23-2002	MOHANLAL, R. W. <i>et al.</i>		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		International Search Report for PCT/US2004/004118, mailed 01/19/2005, 9 sheets	
		International Search Report for PCT/US2004/013587, mailed 01/25/2005, 9 sheets	
		International Search Report for PCT/US2003/037481, mailed 08/23/2005, 3 sheets	
		A. H. KIBBE, Handbook of Pharmaceutical Excipients, 3 rd Edition, Pharmaceutical Press, London, U.K., 2000	
		Affymetrix GeneChip® Expression Analysis, Data Analysis Fundamentals	
		Affymetrix GeneChip® Expression Analysis Technical Manual	
		ARMSTRONG, S. A. <i>et al.</i> , MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia, <i>Nat. Genet.</i> , 30(1):41-47, 2002	
		BOSMA, A. J. <i>et al.</i> , Detection of circulating breast tumor cells by differential expression of marker genes, <i>Clin. Cancer Res.</i> , 8(6):1871-1877, 2002	
		COX, D. R., Regression models and life-tables, <i>Meeting of the Research Section of the Royal Statistical Society</i> , pp. 187-220, 1972	
		DAVIS, I. J. <i>et al.</i> , Cloning of an <i>Alpha-TFEB</i> fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation, <i>Proc. Natl. Acad. Sci. USA</i> , 100(10):6051-6056, 2003	
		DEPRIMO, S. E. <i>et al.</i> , Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification, <i>BMC Cancer</i> , 3(3):1-12, 2003	
		EISEN, M. B. <i>et al.</i> , Cluster analysis and display of genome-wide expression patterns, <i>Proc. Natl. Acad. Sci. USA</i> , 95:14863-14868, 1998	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

W673775.1



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/717,597
				Filing Date	November 21, 2003
				First Named Inventor	Natalie C. TWINE <i>et al.</i>
				Art Unit	1631
				Examiner Name	Mary K. Zeman
Sheet	2	of	2	Attorney Docket Number	031896-012000 (AM 101080)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GOLUB, T. R. <i>et al.</i> , Molecular classification of cancer: class discovery and class prediction by gene expression monitoring, <i>Science</i> , 286(15):531-537, 1999	
		HILL, A. A. <i>et al.</i> , Genomic analysis of gene expression in <i>C. elegans</i> , <i>Science</i> , 290:809-812, 2000	
		HILL, A. A. <i>et al.</i> , Evaluation of normalization procedures for oligonucleotide array data based on spiked cRNA controls, <i>Genome Biology</i> , 2 (12):1-13, 2001	
		KOVACS, G. <i>et al.</i> , The Heidelberg classification of renal cell tumours, <i>J. Pathol.</i> , 183(2):131-133, 1997	
		LOCKHART, D. J. <i>et al.</i> , Expression monitoring by hybridization to high-density oligonucleotide arrays, <i>Nat. Biotechnol.</i> , 14(13):1675-1680, 1996	
		MOTZER, R. J. <i>et al.</i> , Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma, <i>J. Clin. Oncol.</i> , 17(8):2530-2540, 1999	
		PAI, S. M. <i>et al.</i> , Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex, <i>J. Clin. Pharmacol.</i> , 32(3):242-247, 1992	
		PARK, W.Y. <i>et al.</i> , Identification of radiation-specific responses from gene expression profile, <i>Oncogene</i> , 21(55):8521-8528, 2002	
		PERALBA, J.-M. <i>et al.</i> , Pharmacodynamic evaluation of the rapamycin ester CCI-779, <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , Volume 43, March 2002 (2002-2003), pp. 1000-1001, Abstract No. 4961, and 93 rd Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 06-10, 2002	
		POMEROY, S. L. <i>et al.</i> , Supplemental Information for Nature's Paper: Prediction of central nervous system embryonal tumour outcome based on gene expression, pp. 1-104, 2002	
		POMEROY, S. L. <i>et al.</i> , Prediction of central nervous system embryonal tumour outcome based on gene expression, <i>Nature</i> , 415(6870):436-442, 2002	
		RAMASWAMY, S. <i>et al.</i> , Multiclass cancer diagnosis using tumor gene expression signatures, <i>Proc. Natl. Acad. Sci. USA</i> , 98(26):15149-15154, 2001	
		SLONIM, D. K. <i>et al.</i> , Class prediction and discovery using gene expression data, <i>Proceedings of the Fourth Annual International Conference on "Computational Molecular Biology,"</i> TOKYO, JAPAN, pp. 263-272, 2000	
		SNEDECOR, G. W. and COCHRAN, W. G., Correlation, In <i>Statistical Methods</i> , Eight Edition, Chapter 10, pp. 177-195, Iowa State University Press, Ames, Iowa, 1989	
		SU, A. I. <i>et al.</i> , Molecular classification of human carcinomas by use of gene expression signatures, <i>Cancer Res.</i> , 61:7388-7393, 2001	
		VAN DE VIJVER, M. J. <i>et al.</i> , A gene-expression signature as a predictor of survival in breast cancer, <i>N. Engl. J. Med.</i> , 347(25):1999-2009, 2002	
		WHO Handbook for Reporting Results of Cancer Treatment, WHO Offset Publication No. 48, pp. 1-45, World Health Organization, Geneva, Switzerland, 1979	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.